Skip to main content

Advertisement

SpringerLink
Log in

Anticancer Effect of Celecoxib via COX-2 Dependent and Independent Mechanisms in Human Gastric Cancers Cells

  • Original Article
  • Published:
Digestive Diseases and Sciences Aims and scope Submit manuscript

Abstract

Cyclooxygenase-2 (COX-2) inhibitors cause growth inhibition of human gastric carcinoma cells, but it remains unclear whether this is both COX-2 dependent and independent. The related mechanisms remain to be determined. Both low COX-2 expressing gastric carcinoma and high COX-2 expressing gastric carcinoma cells were used to study the effect and mechanisms of celecoxib on gastric carcinoma cell growth. Celecoxib resulted in comparable growth inhibition in AGS cells with stable transfections of small interfering RNA (siRNA) against COX-2 (SAC) and negative control vector (NC) cells. Simultaneously, celecoxib resulted in significant reduction of Bcl-2 and significant increase of p21WAF1 and p27KIP1 in SAC and NC cells. The present study shows that celecoxib causes growth inhibition of gastric carcinoma cells by decreasing Bcl-2 of cyclooxygenase-2-dependent pathway, and by increasing p21WAF1 and p27KIP1 of cyclooxygenase-2-independent pathway. These data extend our knowledge on the effect and mechanisms of celecoxib-induced inhibition of gastric carcinoma cell growth.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2
Fig. 3
Fig. 4

Similar content being viewed by others

References

  1. Cuccurullo C, Fazia ML, Mezzetti A, Cipollone F. COX-2 expression in atherosclerosis: the good, the bad or the ugly? Curr Med Chem. 2007;14:1595–1605. doi:10.2174/092986707780830998.

    Article  PubMed  CAS  Google Scholar 

  2. Brock TG, Peters-Golden M. Activation and regulation of cellular eicosanoid biosynthesis. ScientificWorld Journal. 2007;7:1273–1284. doi:10.1100/tsw.2007.180.

    Article  PubMed  CAS  Google Scholar 

  3. Amir M, Agarwal HK. Role of COX-2 selective inhibitors for prevention and treatment of cancer. Pharmazie. 2005;60:563–570.

    PubMed  CAS  Google Scholar 

  4. Bertagnolli MM. Cox-2 and cancer chemoprevention: picking up the pieces. Recent results in cancer research. Fortschr Krebsforschung. 2007;174:73–78.

    CAS  Google Scholar 

  5. Sarkar FH, Adsule S, Li Y, Padhye S. Back to the future: COX-2 inhibitors for chemoprevention and cancer therapy. Mini Rev Med Chem. 2007;7:599–608. doi:10.2174/138955707780859431.

    Article  PubMed  CAS  Google Scholar 

  6. Nardone G, Rocco A. Chemoprevention of gastric cancer: role of COX-2 inhibitors and other agents. Dig Dis. 2004;22:320–326. doi:10.1159/000083593.

    Article  PubMed  Google Scholar 

  7. Harris RE. Cyclooxygenase-2 (cox-2) and the inflammogenesis of cancer. Subcell Biochem. 2007;42:93–126. doi:10.1007/1-4020-5688-5_4.

    Article  PubMed  Google Scholar 

  8. Marnett LJ, DuBois RN. COX-2: a target for colon cancer prevention. Annu Rev Pharmacol Toxicol. 2002;42:55–80. doi:10.1146/annurev.pharmtox.42.082301.164620.

    Article  PubMed  CAS  Google Scholar 

  9. Xu XC. COX-2 inhibitors in cancer treatment and prevention, a recent development. Anticancer Drugs. 2002;13:127–137. doi:10.1097/00001813-200202000-00003.

    Article  PubMed  CAS  Google Scholar 

  10. Farooqui M, Li Y, Rogers T, et al. COX-2 inhibitor celecoxib prevents chronic morphine-induced promotion of angiogenesis, tumour growth, metastasis and mortality, without compromising analgesia. Br J Cancer. 2007;97:1523–1531. doi:10.1038/sj.bjc.6604057.

    Article  PubMed  CAS  Google Scholar 

  11. Shin VY, Wu WK, Chu KM, et al. Nicotine induces cyclooxygenase-2 and vascular endothelial growth factor receptor-2 in association with tumor-associated invasion and angiogenesis in gastric cancer. Mol Cancer Res. 2005;3:607–615. doi:10.1158/1541-7786.MCR-05-0106.

    Article  PubMed  CAS  Google Scholar 

  12. Da MX, Wu XT, Wang J, et al. Expression of cyclooxygenase-2 and vascular endothelial growth factor-C correlates with lymphangiogenesis and lymphatic invasion in human gastric cancer. Arch Med Res. 2008;39:92–99. doi:10.1016/j.arcmed.2007.06.021.

    Article  PubMed  CAS  Google Scholar 

  13. Maier TJ, Schilling K, Schmidt R, Geisslinger G, Grosch S. Cyclooxygenase-2 (COX-2)-dependent and -independent anticarcinogenic effects of celecoxib in human colon carcinoma cells. Biochem Pharmacol. 2004;67:1469–1478. doi:10.1016/j.bcp.2003.12.014.

    Article  PubMed  CAS  Google Scholar 

  14. Park JH, Kang KH, Kim SH, et al. Expression of Cyclooxygenase-2 and Bcl-2 in human gastric adenomas. Korean J Intern Med. 2005;20:198–204.

    PubMed  CAS  Google Scholar 

  15. Liu XP, Tsushimi K, Tsushimi M, et al. Expression of p21(WAF1/CIP1) and p53 proteins in gastric carcinoma: its relationships with cell proliferation activity and prognosis. Cancer Lett. 2001;170:183–189. doi:10.1016/S0304-3835(01)00589-4.

    Article  PubMed  CAS  Google Scholar 

  16. Belletti B, Nicoloso MS, Schiappacassi M, et al. p27 (kip1) functional regulation in human cancer: a potential target for therapeutic designs. Curr Med Chem. 2005;12:1589–1605. doi:10.2174/0929867054367149.

    Article  PubMed  CAS  Google Scholar 

  17. Wallace JM. Nutritional and botanical modulation of the inflammatory cascade—eicosanoids, cyclooxygenases, and lipoxygenases—as an adjunct in cancer therapy. Integr Cancer Ther. 2002;1:7–37. (discussion 37).

    PubMed  CAS  Google Scholar 

  18. Kakizoe T. Chemoprevention of cancer–focusing on clinical trials. Jpn J Clin Oncol. 2003;33:421–442. doi:10.1093/jjco/hyg090.

    Article  PubMed  Google Scholar 

  19. Shin SS, Byun Y, Lim KM, et al. In vitro structure–activity relationship and in vivo studies for a novel class of cyclooxygenase-2 inhibitors: 5-aryl-2, 2-dialkyl-4-phenyl-3(2H)furanone derivatives. J Med Chem. 2004;47:792–804. doi:10.1021/jm020545z.

    Article  PubMed  CAS  Google Scholar 

  20. Huang MT, Chen ZX, Wei B, et al. Preoperative growth inhibition of human gastric adenocarcinoma treated with a combination of celecoxib and octreotide. Acta Pharmacol Sin. 2007;28:1842–1850. doi:10.1111/j.1745-7254.2007.00652.x.

    Article  PubMed  CAS  Google Scholar 

  21. Cho SJ, Kim N, Kim JS, Jung HC, Song IS. The anti-cancer effect of COX-2 inhibitors on gastric cancer cells. Dig Dis Sci. 2007;52:1713–1721. doi:10.1007/s10620-007-9787-3.

    Article  PubMed  CAS  Google Scholar 

  22. Grosch S, Tegeder I, Niederberger E, Brautigam L, Geisslinger G. COX-2 independent induction of cell cycle arrest and apoptosis in colon cancer cells by the selective COX-2 inhibitor celecoxib. FASEB J. 2001;15:2742–2744.

    PubMed  CAS  Google Scholar 

  23. Makitie AA, Chau M, Lim S, et al. Selective inhibition of cyclooxygenase 2 induces p27kip1 and skp2 in oral squamous cell carcinoma. J Otolaryngol. 2003;32:226–229. doi:10.2310/7070.2003.41701.

    Article  PubMed  Google Scholar 

  24. Narayanan BA, Condon MS, Bosland MC, Narayanan NK, Reddy BS. Suppression of N-methyl-N-nitrosourea/testosterone-induced rat prostate cancer growth by celecoxib: effects on cyclooxygenase-2, cell cycle regulation, and apoptosis mechanism(s). Clin Cancer Res. 2003;9:3503–3513.

    PubMed  CAS  Google Scholar 

  25. Liao WM, Zhang CL, Li FB, Zeng BF, Zeng YX. p21WAF1/CIP1 gene DNA sequencing and its expression in human osteosarcoma. Chin Med J. 2004;117:936–940.

    PubMed  CAS  Google Scholar 

  26. Matsui TA, Sowa Y, Murata H, et al. The plant alkaloid cryptolepine induces p21WAF1/CIP1 and cell cycle arrest in a human osteosarcoma cell line. Int J Oncol. 2007;31:915–922.

    PubMed  CAS  Google Scholar 

  27. Hui CM, Cheung PY, Ling MT, et al. Id-1 promotes proliferation of p53-deficient esophageal cancer cells. Int J Cancer. 2006;119:508–514. doi:10.1002/ijc.21874.

    Article  PubMed  CAS  Google Scholar 

  28. Inadomi T, Tan M, Suzuki H, Shigematsu C. Immunohistochemical evaluation of the probability of skin metastasis in gastric cancer. Eur J Dermatol. 1999;9:214–217.

    PubMed  CAS  Google Scholar 

  29. Xi YG, Ding KY, Su XL, et al. p53 polymorphism and p21WAF1/CIP1 haplotype in the intestinal gastric cancer and the precancerous lesions. Carcinogenesis. 2004;25:2201–2206. doi:10.1093/carcin/bgh229.

    Article  PubMed  CAS  Google Scholar 

  30. Mizokami K, Kakeji Y, Oda S, Maehara Y. Relationship of hypoxia-inducible factor 1alpha and p21WAF1/CIP1 expression to cell apoptosis and clinical outcome in patients with gastric cancer. World J Surg Oncol. 2006;4:94. doi:10.1186/1477-7819-4-94.

    Article  PubMed  Google Scholar 

  31. Bouchard C, Thieke K, Maier A, et al. Direct induction of cyclin D2 by Myc contributes to cell cycle progression and sequestration of p27. EMBO J. 1999;18:5321–5333. doi:10.1093/emboj/18.19.5321.

    Article  PubMed  CAS  Google Scholar 

  32. Narayanan BA. Chemopreventive agents alters global gene expression pattern: predicting their mode of action and targets. Curr Cancer Drug Targets. 2006;6:711–727. doi:10.2174/156800906779010218.

    Article  PubMed  CAS  Google Scholar 

  33. Yang H, Zhang Y, Zhao R, et al. Negative cell cycle regulator 14–3-3sigma stabilizes p27 Kip1 by inhibiting the activity of PKB/Akt. Oncogene. 2006;25:4585–4594. doi:10.1038/sj.onc.1209481.

    Article  PubMed  CAS  Google Scholar 

  34. Anagnostopoulos GK, Stefanou D, Arkoumani E, et al. Bax and Bcl-2 protein expression in gastric precancerous lesions: immunohistochemical study. J Gastroenterol Hepatol. 2005;20:1674–1678. doi:10.1111/j.1440-1746.2005.04057.x.

    Article  PubMed  CAS  Google Scholar 

  35. Triantafyllou K, Kitsanta P, Karamanolis DG, Kittas C, Ladas SD. Epithelial cell turnover, p53 and bcl-2 protein expression during oncogenesis of early and advanced gastric cancer in a Western population. Dig Liver Dis. 2008;40:39–45. doi:10.1016/j.dld.2007.09.010.

    Article  PubMed  CAS  Google Scholar 

Download references

Acknowledgment

This work was supported by the Youth Research Foundation of Shanghai Municipal Health Bureau.

Author information

Authors and Affiliations

  1. Department of Gastroenterology, The Tenth Hospital Affiliated to Tongji University, No. 301, Yanchang Road, 200072, Shanghai, People’s Republic of China

    Hua Liu, Peixin Huang, Xuanfu Xu, Jun Liu & Chuanyong Guo

Authors
  1. Hua Liu
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Peixin Huang
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Xuanfu Xu
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Jun Liu
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Chuanyong Guo
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Hua Liu.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Liu, H., Huang, P., Xu, X. et al. Anticancer Effect of Celecoxib via COX-2 Dependent and Independent Mechanisms in Human Gastric Cancers Cells. Dig Dis Sci 54, 1418–1424 (2009). https://doi.org/10.1007/s10620-008-0510-9

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s10620-008-0510-9

Keywords

Search

Navigation